Non-steroidal progesterone receptor modulators

Bibliography

• PSYCHOYOS A: Hormonal control of ovoimplantation. Vitam. Horm. (1973) 31:201–256.
   PubMedGoogle Scholar
• LYNDON JP, DEMAY O, FUNK CR et aL: Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. (1995) 9:266–2278.
   Google Scholar
• ZHANG Z, FUNK C, GLASSER SR, MULHOLLAND J: Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK-98299. Endocrinology (1994) 135(3):1256–1263.
   PubMedGoogle Scholar
• MANI SK, ALLEN JMC, CLARK JH, BLAUSTEIN JD, O'MALLEY BW: Convergent pathways for steroid hormone- and neurotransmitter-induced rat sexual behavior. Science(1994) 265(5176):1246–1249.
   PubMedGoogle Scholar
• EVENS RW: The steroid and thyroid hormone receptor superfamily. Science (1988) 240:889–895.
   PubMedGoogle Scholar
• TSAI MJ, O'MALLEY BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev Biochem. (1994) 63:451–486.
   PubMed Web of Science ®Google Scholar
• KASTNER P, KRUST A, TURCOTTE B et al.: Two distinct oestrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. (1990) 9(5):1603–1614.
   PubMed Web of Science ®Google Scholar
• CONNEELY OM, MAXWELL BL, TOFT DO, SCHRADER WT, O'MALLEY BW: The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem. Biophys. Res. Commun. (1987) 149(2):493–501.
   PubMedGoogle Scholar
• CONNEELY OM, MULAC-JERICEVIC B, LYDON JP, DE MAYO FJ: Reproductive functions of the progesterone receptor isoforms: lessons from knockout mice. Md. Cell. Endocrin. (2001) 179(1-2):97–103.
   PubMedGoogle Scholar
• MULAC-JERICEVIC B, MULLINAX RA, DEMAYO FJ, LYDON JP, CONNEELY OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 289(5485):1751–1754.
   PubMedGoogle Scholar
• MANGAL RK, WIEHLE RD, POINDEXTER AN, WEIGEL NL: Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid Biochem. Mol. Biol. (1997) 63(4-6):195–202.
   PubMedGoogle Scholar
• FUJIMOTO J, ICHIGO S, HIROSE R, SAKAGUCHI H, TAMAYA T: Clinical implication of expression of progesterone receptor form A and B inRNAs in secondary spreading of gynecologic cancers. J. Steroid Biochem. MM. Biol. (1997) 62(5/6):449–454.
   Google Scholar
• EDGREN RA, STURTEVANT FM: Potencies of oral contraceptives. Am. J. Obst. Gynecol. (1976) 125(8):1029–1038.
   PubMedGoogle Scholar
• BROGDEN RN, GOA KL, FAULDS D: Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs (1993) 45(3):384–409.
   PubMedGoogle Scholar
• GLASIER A, BAIRD D: The effects of self-administering emergency contraception. New Engl. J. Med (1998) 339:1.
   PubMed Web of Science ®Google Scholar
• SLAYDEN OD, ZELINSKI-WOOTEN MB, CHWALISZ K, STOUFFER RL, BRENNER RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK-137316: morphometric assessment of the uterus and oviduct. Human Reprod. (1998) 13 (2):269–277.
   PubMed Web of Science ®Google Scholar
• ZELINSKI-WOOTEN MB, SLAYDEN OD, CHWALISZ K, HESS DL, BRENNER RIVI, STOUFFER RL: Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK-137316: establishment of a regimen that permits normal menstrual cyclicity. Human Reprod. (1998) 13(2):259–267.
   PubMedGoogle Scholar
• KETTEL LM, MURPHY, AA, MORALES AJ, YEN SS: Clinical efficacy of the antiprogesterone RU-486 in the treatment of endometriosis and uterine fibroids. Human Reprod. (1994) 9\(Supp1.1):116–120.
   Google Scholar
• KETTEL LM, MURPHY AA, MORALESAJ, YEN SS: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU-486). Am. J. Obst. Gynecol. (1998) 178:1151–1156.
   PubMed Web of Science ®Google Scholar
• MURPHY AA, KETTEL LM, MORALES AJ, ROBERTS VJ, YEN SS: Regression of uterine leiomyomata in response to the antiprogesterone RU-486. Clin. Endocrinol. Metabol. (1993) 76:513–517.
   Google Scholar
• BRENNER RIVI, SLAYDEN OD, CRITCHLEY HOD: Antiproliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction (2002) 124(2):167–172.
   PubMedGoogle Scholar
• KARAS RH, VAN EICKELS M, LYDON JP et al.: A complex role for the progesterone receptor in the response to vascular injury. I Clin. Investigation (2001) 108:611–618.
   PubMed Web of Science ®Google Scholar
• ROSANO GMC, FINI M: Comparative cardiovascular effects of different PR agonists in menopause. Int. J. Fel-WM, and WomenS Medicine (2001) 46:248–256.
   PubMedGoogle Scholar
• SKOUBY SO, PETERSEN KR: Clinicalexperience with the recently developed progestogens. Int. J. Feral:0,(1991) 36\(Supp1.1):32–37.
   Google Scholar
• WELLINGTON K, PERRY CM: Estradiol valerate/dienogest. Drugs (2002) 62:491–504.
   PubMed Web of Science ®Google Scholar
• ZHI L, TEGLEY CM, PIO B et al.: Non-steroidal progesterone receptor antagonists based on 6-thiophenylhydroquinolines. Biooig. Med Chem. Lett. (2000) 10:415–418.
   PubMed Web of Science ®Google Scholar
• ZHANG P, TEREFENKO EA, FENSOME A et al.: Potent non-steroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg. Med. Chem. Lett. (2002)12:787–790.
   PubMed Web of Science ®Google Scholar
• BECK CA, WEIGEL NL, MOYER ML, NORDEEN SK, EDWARDS DP: The progesterone antagonist RU-486 acquires agonist activity upon stimulation of cAMP signalling pathways. Proc. Nati Acad. Sci. USA (1993) 90:4441–4445.
   PubMedGoogle Scholar
• ZHANG Z, LUNDEEN SG, ZHU Y, CARVER JM, WINNEKER RC: In vitro characterization of trimegestone: a new potent and selective progestin. Steroids (2000) 65:637–643.
   PubMed Web of Science ®Google Scholar
• ZHANG P, TEREFENKO EA, FENSOME A, WROBEL J, WINNEKER R, ZHANG Z: Novel 6-aryl-1.4-dihydrobenzo [d]oxazine-2-thiones as potent, selective and orally-active non-steroidal progesterone receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(7):1313–1316.
   Google Scholar
• FENSOME A, KOKO M, WROBEL J et al.: Novel 5-ary1-1,3-dihydro-indole-2-thiones: potent, orally-active progesterone receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(7):1317–1320.
   PubMedGoogle Scholar
• LUNDEEN SG, ZHANG Z, ZHU Y, CARVER JM, WINNEKER RC: Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. Steroid Biochem. Moi Biol. (2001) 78(2):137–143.
   PubMedGoogle Scholar
• HORWITZ KB, TUNG L, TAKIMOTO GS: Progestins, progesterone receptors and breast cancer. Hopp. Cancer (1996) 283–306.
   Google Scholar
• KLIJN JGM, SETYONO-HAN B, FOEKENS JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids (2000) 65:825–830.
   PubMedGoogle Scholar
• MICHNA H, PARCZYK K, SCHNEIDER MR, NISHINO Y: Differentiation therapy with progesterone antagonists. Ann. NY Acad. Sci. (1995) 761:224–247.
   PubMed Web of Science ®Google Scholar
• ROSEN J, DAY A, JONES TK, JONES ETT, NADZAN AM, STEIN RB: Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem. (1995) 38(25):4855–4874.
   PubMedGoogle Scholar
• ZHANG P, TEREFENKO EA, WROBEL J et al.: Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. Bioorg. Med. Chem. Lett. (2001) 11(20):2747–2750.
   PubMedGoogle Scholar
• FENSOME A, BENDER R, COHEN J et al.: New progesterone receptor antagonists: 3, 3-disubstituted-5-aryloxindoles. Bioorg. Med. Chem. Lett. (2002) 12(23):3487–3490.
   PubMedGoogle Scholar
• ZHANG P, TEREFENKO EA, FENSOME A et al.: 6-Ary1-1,4-dihydro-benzoM [1,3]oxazin-2-ones: a novel class of potent, selective and orally-active nonsteroidal progesterone receptor antagonists. Med. Chem. (2002) 45(20):4379–4382.
   Google Scholar
• PHILIBERT D, BOUCHOUX F, DEGRYSE M, LECAQUE D, PETIT F, GAILLARD M: The pharmacological profile of a novel norpregnance progestin (trimegestone). Cynecol. Endocrinol. (1999) 13:316–326.
   PubMed Web of Science ®Google Scholar
• ZHI L, TEGLEY CM, PIO B et al.: 5-Benzylidene-1,2-dihydrochromeno [3,4-11quinolines as selective progesterone receptor modulators. J. Med. Chem. (2003) 46(19):4104–4112.
   PubMedGoogle Scholar
• MULAC-JERICEVIC B, LYDON JP, DEMAYO FJ, CONNEELY OM: Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Nati Acad. Sci. USA (2003) 100(17):9744–9749.
   PubMedGoogle Scholar